These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10384824)

  • 1. The health care burden of unstable angina.
    Kong DF; Blazing MA; O'Connor CM
    Cardiol Clin; 1999 May; 17(2):247-61. PubMed ID: 10384824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes.
    McElwee NE; Johnson ER
    Am J Cardiol; 1997 Aug; 80(4A):39B-43B. PubMed ID: 9291245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the clinical and economic burden of coronary artery disease: 1986-1998.
    Eisenstein EL; Shaw LK; Anstrom KJ; Nelson CL; Hakim Z; Hasselblad V; Mark DB
    Med Care; 2001 Aug; 39(8):824-35. PubMed ID: 11468501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications.
    Hillegass WB; Newman AR; Raco DL
    Pharmacoeconomics; 2001 Jan; 19(1):41-55. PubMed ID: 11252545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical predictors easily obtained at presentation predict resource utilization in unstable angina.
    Calvin JE; Klein LW; VandenBerg BJ; Meyer P; Ramirez-Morgen LM; Parrillo JE
    Am Heart J; 1998 Sep; 136(3):373-81. PubMed ID: 9736126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unstable angina: cost of conservative and invasive strategies using TIMI3 B as a model.
    Conti CR
    Clin Cardiol; 1995 Apr; 18(4):187-8. PubMed ID: 7788944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary artery stents in the treatment of ischaemic heart disease: a rapid and systematic review.
    Meads C; Cummins C; Jolly K; Stevens A; Burls A; Hyde C
    Health Technol Assess; 2000; 4(23):1-153. PubMed ID: 11074393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The invasive management of angina: issues for consumers and commissioners.
    Gunnell D; Harvey I; Smith L
    J Epidemiol Community Health; 1995 Aug; 49(4):335-43. PubMed ID: 7650455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction.
    Mahoney EM; Jurkovitz CT; Chu H; Becker ER; Culler S; Kosinski AS; Robertson DH; Alexander C; Nag S; Cook JR; Demopoulos LA; DiBattiste PM; Cannon CP; Weintraub WS;
    JAMA; 2002 Oct; 288(15):1851-8. PubMed ID: 12377083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can improved quality of care reduce the costs of managing angina pectoris?
    Cleland JG
    Eur Heart J; 1996 Mar; 17 Suppl A():29-40. PubMed ID: 8737199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease.
    Yock CA; Boothroyd DB; Owens DK; Garber AM; Hlatky MA
    Am J Med; 2003 Oct; 115(5):382-9. PubMed ID: 14553874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy.
    Solomon DH; Stone PH; Glynn RJ; Ganz DA; Gibson CM; Tracy R; Avorn J
    J Am Coll Cardiol; 2001 Oct; 38(4):969-76. PubMed ID: 11583866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing cost aspects of coronary artery bypass graft surgery with coronary artery stenting.
    Birim Ö; Bogers AJ; Kappetein AP
    J Cardiovasc Surg (Torino); 2012 Oct; 53(5):641-50. PubMed ID: 22252542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: an analysis from the C-SIRIUS trial.
    Rinfret S; Cohen DJ; Tahami Monfared AA; Lelorier J; Mireault J; Schampaert E
    Am J Cardiovasc Drugs; 2006; 6(3):159-68. PubMed ID: 16780389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Can PCI with drug-eluting stents replace coronary artery bypass surgery? A comparative economic analysis regarding both therapeutic options based on clinical 12-month data reflecting the German social health care insurance system].
    Fricke FU; Silber S
    Herz; 2005 Jun; 30(4):332-8. PubMed ID: 15965811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
    Plosker GL; Ibbotson T
    Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic consequences of routine coronary angiography in low- and intermediate-risk patients with unstable angina pectoris.
    Desai AS; Solomon DH; Stone PH; Avorn J
    Am J Cardiol; 2003 Aug; 92(4):363-7. PubMed ID: 12914862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of costs associated with CABG and PTCA.
    Hlatky MA
    Ann Thorac Surg; 1996 Feb; 61(2 Suppl):S30-2; discussion S33-4. PubMed ID: 8572830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina.
    Henderson RA; Pocock SJ; Sharp SJ; Nanchahal K; Sculpher MJ; Buxton MJ; Hampton JR
    Lancet; 1998 Oct; 352(9138):1419-25. PubMed ID: 9807988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.